BIOTRICITY INC. SEC 10-Q Report

Biotricity Inc., a leading provider of remote monitoring solutions for preventative care, has released its latest Form 10-Q report, showcasing notable improvements in both financial and operational performance. The report highlights the company's continued growth and strategic focus on commercializing its innovative product lines.

Financial Highlights

• Revenue: $3.87 million, reflecting an increase from the previous year's $3.20 million, driven by higher technology fees and device sales.
• Gross Profit: $3.12 million, up from $2.36 million in the prior year, indicating improved cost management and operational efficiency.
• (Loss) Profit from Operations: $0.28 million, compared to a loss of $1.12 million in the previous year, showcasing a significant turnaround in operational performance.
• Net Loss Before Income Taxes: $(0.67) million, a substantial improvement from the $(3.69) million loss in the prior year, highlighting effective cost control measures.
• Net Loss Attributable to Common Stockholders: $(0.75) million, compared to $(6.95) million in the previous year, demonstrating a marked reduction in losses.
• Loss Per Share, Basic and Diluted: $(0.029), a significant improvement from $(0.490) in the prior year, reflecting better financial performance and reduced losses.

Business Highlights

• Revenue Segments: The company reported revenue from two primary sources: technology fees and device sales. Technology fees accounted for $3,371,392, while device sales contributed $502,601 for the three months ended June 30, 2025.
• Geographical Performance: The company operates in the United States and Canada, with the U.S. being the primary market. The financial statements are expressed in U.S. dollars, and the company has not reported significant long-lived assets outside the U.S.
• New Product Launches: The company is focused on commercializing its Bioflux, Biocore, and Biocare product lines, which are part of its ecosystem of technologies for remote monitoring in preventative care.
• Future Outlook: Management anticipates continued revenue growth and improved liquidity through business development and additional equity and debt capitalization. The company plans to devote significant resources to capital expenditures, research and development, and marketing and sales as it proceeds with the commercialization of its product lines.

SEC Filing: BIOTRICITY INC. [ BTCY ] - 10-Q - Aug. 14, 2025